Lexpos News

The Department of Health and Social Care (DHSC) has today (18/12/2025) confirmed the following initial list of price concessions for December 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.21 Bumetanide 1mg tablets 28 £2.51 Carbocisteine 375mg capsules 120 £5.29 (previously £2.95) Cefalexin 125mg/5ml oral suspension sugar free 100 £4.64 Cefalexin 500mg tablets 21 [...]

The post December 2025 Price Concessions 1st Update appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (18/12/2025) confirmed the following initial list of price concessions for December 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.21 Bumetanide 1mg tablets 28 £2.51 Carbocisteine 375mg capsules 120 £5.29 (previously £2.95) Cefalexin 125mg/5ml oral suspension sugar free 100 £4.64 Cefalexin 500mg tablets 21 [...]

The post December 2025 Price Concessions 1st Update appeared first on Community Pharmacy England.

Teenage pregnancy has long been a marker of health inequality in England. The provision of locally commissioned sexual health services, including those provided by community pharmacies, has been part of local authority efforts to tackle local health inequalities and improve outcomes. A report from the Local Government Association (LGA)  highlights how local government working with [...]

The post Reducing teenage pregnancy – How community pharmacy and local government collaboration has driven progress appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.